Mucinous cystadenocarcinoma pathophysiology

Mucinous cystadenocarcinoma Microchapters
Home
Patient Information
Overview
Historical Perspective
Pathophysiology
Causes
Differentiating Mucinous Cystadenocarcinoma from other Diseases
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Mucinous cystadenocarcinoma pathophysiology On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Mucinous cystadenocarcinoma pathophysiology All Images X-rays Echo and Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Mucinous cystadenocarcinoma pathophysiology
CDC on Mucinous cystadenocarcinoma pathophysiology
Mucinous cystadenocarcinoma pathophysiology in the news
Blogs on Mucinous cystadenocarcinoma pathophysiology
Directions to Hospitals Treating Mucinous cystadenocarcinoma
Risk calculators and risk factors for Mucinous cystadenocarcinoma pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]

Pathogenesis

• Mucinous cystadenocarcinoma of the ovary is a rare malignant ovarian mucinous tumor. This type can account for 5-10% of all ovarian mucinous tumors. It is a type of ovarian epithelial tumor.
• Retrospective studies have suggested that many mucinous carcinomas initially diagnosed as primary to the ovary have in fact metastasised from another site.

Associated Conditions

• Malignant transformation of a mature cystic teratoma